

Lilly announces leadership changes

08 August 2019 | News

Darren Carroll, senior vice president of corporate business development, will retire at the end of August after 22 years of service with the company



Eli Lilly and Company has announced several leadership changes in the company's corporate business development, oncology R&D, and managed healthcare services organizations.

Darren Carroll, senior vice president of corporate business development, will retire at the end of August after 22 years of service with the company. Carroll has led Lilly's corporate business development organization for nearly a decade, including the \$8.1 billion acquisition of Loxo Oncology earlier this year, the largest acquisition in Lilly's history.

In two related moves, Phil Johnson, senior vice president and treasurer, will assume additional duties overseeing merger & acquisition activity, while Heather Wasserman, Ph.D., has been promoted to vice president of corporate business development, with responsibility for business development transactions, emerging technologies and innovation, and venture capital.

The company also announced that Levi Garraway, M.D., Ph.D., has resigned from his position as senior vice president of oncology research and early phase development in order to pursue other opportunities. Josh Bilenker, M.D., CEO of Loxo Oncology, a wholly owned subsidiary of Lilly, will lead oncology research and early phase development in the interim, in addition to his current responsibilities.

In addition, Frank Cunningham has been promoted to senior vice president of managed healthcare services, in recognition of the critical role his organization plays in leading the company's interactions and negotiations with payer customers. Managed healthcare services works to ensure patients in the U.S. have broad access to Lilly medicines.